OKUR
ONKURE THERAP-A (OKUR)
NASDAQ
$4.21+$0.005 (+0.12%)
Price as of Jun 23, 2026 4:35 PM EDT
  • $179.4M
    Market Cap
  • 64.06%
    1-Year Change
  • Biotechnology
    Industry

Key Performance

More
  • Earnings Score: N/A
  • Momentum Score: 56
  • True Yield: N/A
  • Financial Health Score: N/A
TradeSmith Loading

Latest Research & News

No data found

No data found

Peers

Statistics

More
Day Range
$4.13
$4.55
$4.20
1-Year Range
$2.00
$5.27
$4.20
Latest Close$4.20
Change
-$0.24 (-5.71%)
Volume292,286
Market Cap$179.4M
Shares Outstanding40.4M
P/E (TTM)-1.03
Diluted EPS (TTM)-$4.33
Enterprise Value-$12.8M

Information as of 06/23/2026

Company Profile

ONKURE THERAPEUTICS INC
ONKURE THERAPEUTICS INC
https://onkuretherapeutics.com
$179.4M
Market Cap
-$58.7M
Net Income
Sector: Healthcare
Industry: Biotechnology
6707 Winchester Circle, Boulder, CO, United States, 80301
720-307-2892

OnKure Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery and development of precision medicines that target biologically validated drivers of cancers and other diseases. Its lead product candidate includes OKI-219, a selective inhibitor of phosphoinositide 3-kinase alpha (PI3Ka) harboring the H1047R mutation that is in Phase 1 clinical trial for the treatment of solid tumors, including breast cancer. The company was founded in 2011 and is headquartered in Boulder, Colorado.

Key Executives

  • Nicholas A. Saccomano
  • Samuel Agresta
  • Jason A. Leverone
  • Isaac Manke
  • Dylan Hartley

Current Ownership Distribution

  • Institutions69.0M (88.90%)
  • Insiders7.9M (10.19%)
  • Mutual Funds705,680 (0.91%)
  • Other0 (0.00%)